<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

Destination
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous with a booming weight loss drug market that could hit $139 billion by 2030.Read more... [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more... [...]

Match Score: 146.48

Destination
Eli Lilly and Novo Nordisk are tackling heart health next

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health.Read more... [...]

Match Score: 125.95

thenextweb
Hacking group claims it breached Novo Nordisk and demanded $25m

A cyber-extortion group calling itself FulcrumSec said on Monday that it had stolen roughly 1.3 terabytes of data from Novo Nordisk, the Danish maker of the weight-loss drugs Wegovy and Ozempic, and h [...]

Match Score: 104.36

Destination
Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars

The first GLP-1 pill could be in medicine cabinets sooner than expected.Read more... [...]

Match Score: 100.54

qz
Novo Nordisk is asking a court to immediately block Eli Lilly's weight loss drug ads

Novo says Lilly's ads for Zepbound and Mounjaro rely on outdated data and omit newer, higher-dose versions of Wegovy and Ozempic [...]

Match Score: 100.14

Destination
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.Read more... [...]

Match Score: 98.49

thenextweb
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]

Match Score: 98.45

thenextweb
Novo Nordisk’s owner backs an Italian fund to grow drug startups beyond Denmark

Novo Holdings, the investment company that controls Novo Nordisk and holds the wealth of the Novo Nordisk Foundation, is backing a fund aimed at Italian drug startups, according to Bloomberg. The mov [...]

Match Score: 98.18

Destination
Novo Nordisk and Eli Lilly ink deals with Trump to cut weight loss drug prices

Prices of Eli Lilly's and Novo Nordisk's GLP-1 drugs will drop in some cases — in exchange for partially expanded Medicare coverage [...]

Match Score: 95.96